What is the global market size of Fetal Bovine Serum Market?

Global Fetal Bovine Serum Market size was valued at USD 1.38 Billion in 2021 and is poised to grow from USD 1.57 Billion in 2022 to USD 4.52 Billion by 2030, by rising at a CAGR of 14.1% during the forecast period (2023-2030).

Who are the key vendors in the Global Fetal Bovine Serum Market?

The global fetal bovine serum market is highly competitive and characterized by the presence of several key players. These companies strive to gain a competitive edge by focusing on product quality, expanding their product portfolios, and engaging in strategic partnerships and acquisitions. Thermo Fisher Scientific Inc., a leading player in the market, offers a wide range of FBS products under its Gibco brand, emphasizing quality and consistency to meet the diverse needs of researchers. Merck KGaA, another major player, provides a comprehensive portfolio of FBS products, including serum-free alternatives, catering to the growing demand for animal component-free culture systems. GE Healthcare is actively involved in expanding its FBS manufacturing capabilities and product offerings to meet the rising global demand. Tissue Culture Biologicals, Atlanta Biologicals Inc., and HiMedia Laboratories Pvt. Ltd. are prominent players focusing on delivering high-quality FBS products and addressing specific customer requirements. These companies emphasize stringent quality control measures to ensure the reliability and consistency of their FBS offerings. 'Thermo Fisher Scientific Inc. (US)', 'Merck KGaA (Germany)', 'GE Healthcare (US)', 'Tissue Culture Biologicals (US)', 'HiMedia Laboratories Pvt. Ltd. (India)', 'Atlanta Biologicals Inc. (US)', 'Sigma-Aldrich Corporation (US)', 'Rocky Mountain Biologicals (US)', 'PAN-Biotech GmbH (Germany)', 'Bovogen Biologicals Pty Ltd. (Australia)', 'Biowest SAS (France)', 'Biological Industries Israel Beit Haemek Ltd. (Israel)', 'Corning Incorporated (US)', 'Sera Laboratories International Ltd. (UK)', 'Caisson Laboratories Inc. (US)', 'Hyclone Laboratories Inc. (US)', 'Lanzhou Minhai Biotechnology Co., Ltd. (China)', 'Moregate BioTech (UK)', 'Gemini Bio-Products (US)', 'Lampire Biological Laboratories (US)'

What is the key driver of Global Fetal Bovine Serum Market?

The biopharmaceutical industry witnessed significant growth, with a focus on developing innovative therapeutic solutions. FBS, being an essential component in cell culture-based research, found extensive utilization in drug discovery, preclinical testing, and biologics production. The increasing investment in biopharmaceutical R&D activities drove the demand for FBS.

What is the key market trend for Global Fetal Bovine Serum Market?

Shift towards Animal Component-Free Culture Systems: The industry observed a trend towards the development and adoption of animal component-free culture systems. Researchers and manufacturers sought to reduce the reliance on FBS and transition to defined media formulations that do not contain animal-derived components. This trend aimed to address ethical concerns, enhance experimental reproducibility, and simplify regulatory compliance.

Which region accounted for the largest share in Global Fetal Bovine Serum Market?

In 2022, North America emerged as the dominant region in the global fetal bovine serum (FBS) market, capturing a significant share of 38.0%. This growth can be attributed to the increasing government expenditure on research and development (R&D) activities. The United States, in particular, is renowned for having one of the strongest R&D ecosystems globally. Notably, the biotechnology industry in the U.S. witnessed a substantial 94% growth in R&D expenditure from 2016 to 2021, reaching a total of USD 88.6 billion, as reported in a July 2022 news article. Additionally, factors such as the growing focus on developing biopharmaceutical products, the presence of established market players, and robust healthcare infrastructure further contribute to the market's expansion in the region.

Fetal Bovine Serum Market Size, Share, Growth Analysis, By End-user(Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Other End Users), By Application(Biopharmaceutical Production, Monoclonal antibodies, Vaccines production, Other therapeutic proteins), By Type(Serum-free Media, CHO Media, HEK 293 Media, BHK Media), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35I2208 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 108 | Figures: 76

Fetal Bovine Serum Market Insights

Fetal Bovine Serum Market size was valued at USD 1.79 Billion in 2023 and is poised to grow from USD 2.04 Billion in 2024 to USD 5.88 Billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).

Growing investments in cell research and biopharmaceutical research are projected to primarily drive up the demand for fetal bovine serum over the coming years. Advancements in cell culture technologies and rising demand for regenerative medicine are also expected to bolster fetal bovine serum market growth in the future. Rising incidence of chronic diseases and growing demand for cell therapies for their treatment are also expected to create new opportunities for fetal bovine serum companies in the long run. On the contrary, supply chain constraints, availability of alternatives, and variability in batches are some restraints that are slated to impede the adoption of fetal bovine serum in the future. Ethical concerns about animal testing are estimated to emerge as a key constraint for fetal bovine serum companies going forward.

Fetal Bovine Serum Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Fetal Bovine Serum Market size was valued at USD 1.57 billion in 2022 and is poised to grow from USD 1.79 billion in 2023 to USD 5.15 billion by 2031, by rising at a CAGR of 14.1% during the forecast period (2024-2031).

Fetal bovine serum providers should focus on solving the ethical concerns surrounding the production of their product to maximize business scope. Targeting countries where investments in cell research are high is expected to offer better returns on investments for fetal bovine serum providers. Fetal bovine serum companies should also try to achieve consistency in different batches of fetal bovine serum to improve consistency of results. 'Thermo Fisher Scientific Inc. (US)', 'Merck KGaA (Germany)', 'GE Healthcare (US)', 'Tissue Culture Biologicals (US)', 'HiMedia Laboratories Pvt. Ltd. (India)', 'Atlanta Biologicals Inc. (US)', 'Sigma-Aldrich Corporation (US)', 'Rocky Mountain Biologicals (US)', 'PAN-Biotech GmbH (Germany)', 'Bovogen Biologicals Pty Ltd. (Australia)', 'Biowest SAS (France)', 'Biological Industries Israel Beit Haemek Ltd. (Israel)', 'Corning Incorporated (US)', 'Sera Laboratories International Ltd. (UK)', 'Caisson Laboratories Inc. (US)', 'Hyclone Laboratories Inc. (US)', 'Lanzhou Minhai Biotechnology Co., Ltd. (China)', 'Moregate BioTech (UK)', 'Gemini Bio-Products (US)', 'Lampire Biological Laboratories (US)'

Surging use of monoclonal antibodies, vaccines, and cell therapies for the treatment of various diseases has resulted in high demand for biopharmaceutical research around the world. Fetal bovine serum is a key supplement in cell culture media required for biopharmaceutical production thereby making this a key fetal bovine serum market growth driver.

Use in 3D Cell Culture: Investments in 3D cell culture are increasing rapidly around the world and this is expected to present new opportunities for fetal bovine serum providers in the future. Fetal bovine serum can play a vital role in maintaining stability of complex 3D cell culture systems over the coming years and boost revenue generation potential for market players.

North America is forecasted to account for a high fetal bovine serum market share on a global level. Rising healthcare research and development activity, growing emphasis on improving biopharmaceutical production, and presence of multiple pharmaceutical companies are key factors allowing this region to maintain its dominant stance. The United States is slated to spearhead revenue generation in North America followed by Canada over the coming years. Availability of supportive government funding for medical research and rising investments in stem cell and regenerative medicine research are also slated to create new opportunities for fetal bovine serum providers in this region.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Fetal Bovine Serum Market Insights

Fetal Bovine Serum Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Fetal Bovine Serum Market?

Who are the key vendors in the Fetal Bovine Serum Market?

What is the key driver of Fetal Bovine Serum Market?

What is the key market trend for Fetal Bovine Serum Market?

Which region accounted for the largest share in Fetal Bovine Serum Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300